id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0300-0001,FDA,FDA-2003-N-0300,"Certain Antibiotic New Animal Drug Products and Use Combinations Subject to Listings in the New Animal Drug Regulations; Drug Efficacy Study
Implementation; Notice of Opportunity for Hearing",Notice,Notice of Opportunity of Hearing,2003-12-12T05:00:00Z,2003,12,,,2025-03-13T19:16:21Z,03-20241,0,0,0900006480493c5c
FDA-2003-N-0300-0003,FDA,FDA-2003-N-0300,Memorandum from FDA to FDA DDM,Other,Separation of Functions,2003-12-12T05:00:00Z,2003,12,,,2025-03-13T19:36:08Z,,0,0,0900006480493c87
FDA-2003-N-0300-0002,FDA,FDA-2003-N-0300,"Certain Antibiotic New Animal Drug Products and Use Combinations Subject to Listings in the New Animal Drug Regulations; Drug Efficacy Study
Implementation; Notice of Opportunity for Hearing; Correction",Notice,Correction,2003-12-12T05:00:00Z,2003,12,2003-08-05T04:00:00Z,2003-11-07T04:59:59Z,2025-03-13T19:30:24Z,03-25343,0,0,0900006480493c7d